Kadmon Holdings (NYSE:KDMN) announced that CEO Harlan W. Waksal will present at several upcoming virtual investor conferences. Key presentations include:
- H.C. Wainwright Conference: September 14, 2020, 11:00 a.m. ET
- Cantor Fitzgerald Conference: September 15, 2020, 1:20 p.m. ET
- Oppenheimer Summit: September 21, 2020, 2:30 p.m. ET
Waksal will also participate in investor meetings at the Citi and Morgan Stanley conferences. Live audio webcasts will be available on Kadmon's website.
Kadmon Holdings, Inc. (NYSE: KDMN) announced the appointment of Nancy Miller-Rich to its Board of Directors. With 35 years in the pharmaceutical industry, her experience includes leadership roles at Merck and Schering-Plough. As the company prepares for key milestones, including the NDA submission for belumosudil for chronic graft-versus-host disease (cGVHD), her expertise in global business development is expected to enhance Kadmon's strategies. Belumosudil has received Breakthrough Therapy Designation and is under review for cGVHD treatment.
Kadmon Holdings, Inc. (NYSE:KDMN) announced the appointment of Nancy Miller-Rich to its Board of Directors, bringing over 35 years of pharmaceutical industry experience. Her past roles include Senior Vice President at Merck, where she focused on global business development. The company anticipates Miller-Rich's insights will enhance its strategic plans, particularly regarding the NDA submission for belumosudil, a treatment for chronic graft-versus-host disease. Belumosudil has received Breakthrough Therapy and Orphan Drug designations from the FDA.